¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

»ï¼º¼­¿ïº´¿ø Á¦18ȸ »ï¼ºÈ²¹Ý½ÉÆ÷Áö¿ò : 2018-10-13

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
»ï¼º¼­¿ïº´¿ø Á¦18ȸ »ï¼ºÈ²¹Ý½ÉÆ÷Áö¿ò : 2018-10-13
±³À°ÀÏÀÚ : 2018-10-13
±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø º»°ü ÁöÇÏ1Ãþ ´ë°­´ç  
±³À°ÁÖÁ¦ : Á¦18ȸ »ï¼ºÈ²¹Ý½ÉÆ÷Áö¿ò 
ÁÖÃÖ±â°ü : »ï¼º¼­¿ïº´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú  
´ã´çÀÚ : Ç¥¼ºÈñ
¿¬¶ôó : 02-3410-3568  
À̸ÞÀÏ : sunghee.pyo@samsung.com      
±³À°Á¾·ù : ¾È°ú±âŸ
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í »çÀüµî·Ïºñ (Àü°øÀÇ-4¸¸¿ø, Àü¹®ÀÇ-6¸¸¿ø) ÇöÀåµî·Ïºñ (Àü°øÀÇ-6¸¸¿ø, Àü¹®ÀÇ-8¸¸¿ø)      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 09:00~09:10 Subclinical neovascularization in nonexudative AMD  ¹Ú¿µÈÆ(°¡Å縯´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 09:10~09:20 OCTA findings and treatment response in exudative AMD  ¹è°ÇÈ£(¼º±Õ°ü´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 09:20~09:30 Automated segmentation of lesions in AMD  ±èÇüÂù(°Ç±¹´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 09:30~09:40 OCTA biomarkers of functional outcome predictors in diabetic retinopathy  ±è¼º¿ì(°í·Á´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 09:40~09:50 Changes in FAZ in various retinal conditions  ¿ÀÀç·É(°í·Á´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 09:50~10:00 Potential role of OCT for neurodegenerative disease  ¾ÈÁöÀ±(¼­¿ï´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 10:00~10:10 New and emerging therapies for neovascular AMD  ¹Ú¿îö(¼­¿ï´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 10:10~10:20 Treatment options for submacular hemorrhage  ±èÀçÈÖ(±è¾È°úº´¿ø) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 10:20~10:30 Non-typical AMD  À̼ºÃ¶(¿¬¼¼´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 10:30~10:40 Updates on intraocular sustained drug delivery  ¼Û¼öÁ¤(¼º±Õ°ü´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 10:40~10:50 Lessons learned from DRCR.net protocols  ¹Ú¼ºÇ¥(ÇѸ²´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 10:50~11:00 Subthreshold laser therapies  Á¶ÈñÀ±(ÇѾç´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 11:30~11:40 Surgical options for large macular holes  °­¼¼¿õ(¼º±Õ°ü´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 11:40~11:50 Surgical outcomes of lamellar macular hole  ¼ÕÁØÈ«(Çѱæ¾È°úº´¿ø) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 11:50~12:00 When and how to treat epiretinal membrane  ³²µ¿Èç(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 12:00~12:10 When and how to treat myopic traction maculopathy  ÀÌ¿ø±â(°¡Å縯´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 12:10~12:20 Treatment of optic pit maculopathy  º¯¼®È£(¿¬¼¼´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 13:30~13:40 PDR surgery: cutter only dissection, scissors vs cutter, viscodissection  ±èÁß°ï(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 13:40~13:50 Pre- and intra-operative anti-VEGF for diabetic vitrectomy  ¹ÚÅ°ü(¼øõÇâ´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 13:50~14:00 ERM / ILM removal in DR  À¯Çü°ï(¼­¿ï´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 14:00~14:10 Surgical strategies for PVR  ÁøÈñ½Â(ÀÎÇÏ´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 14:10~14:20 Retinal detachment after open globe injury  Á¶¿µÁØ(Ãæ³²´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 14:20~14:30 3D Digitally Assisted Vitrectomy  ¹Ú±ÔÇü(¼­¿ï´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 15:00~15:10 Surgery for pediatric retinal detachment  ÀÌÁÖ¿ë(¿ï»ê´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 15:10~15:20 Combined lensectomy and vitrectomy for pediatric retinal diseases including ROP  ±è»óÁø(¼º±Õ°ü´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 15:20~15:30 Diagnostic vitrectomy: surgical considerations  ±èÇö¿õ(ÀÎÁ¦´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 15:30~15:40 Surgery for exudative retinal detachment: when and how?  ½ÅÀçÇÊ(°æºÏ´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 15:40~15:50 Various techniques in management of dropped nucleus  À̽¿ì(µ¿±¹´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 15:50~16:00 My tips in the management of dislocated IOL-I  ÃÖ°æ½Ä(ÃáõÇâ´ë) 
±³À°½Ã°£ 10¿ù 13ÀÏ ´ë°­´ç 16:00~16:10 My tips in the management of dislocated IOL-II  À±Èñ¼º(¼º¸ð¾È°úº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" »ï¼º¼­¿ïº´¿ø Á¦18ȸ »ï¼ºÈ²¹Ý½ÉÆ÷Áö¿ò : 2018-10-13""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ºÎ»ê´ëÇб³º´¿ø 2018³â ³»°ú ¿¬¼ö°­Á : 2018-10-13
´ÙÀ½±Û 2018³â ´ëÇÑÃé´ãµµÇÐȸ Ãß°èÇмú´ëȸ : 2018-10-13
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
17 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ôÃߺ´¿ø 8¿ù ¿ù·ÊÁý´ãȸ : 2018-08-02 0 369 2018-07-28
16 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-08-01 0 375 2018-07-28
15 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ Á¦3Â÷ CADAVER WORKSHOP : 2018-07-29 0 728 2018-07-28
14 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø ¿µ»óȹµæÀÇ ±â¼úÀû Ãø¸é°ú Æó¾Ï °ËÁø : 2018-07-29 0 743 2018-07-28
13 ¼­¿ï ´ëÇѺÎÀÎÁ¾¾çÇÐȸ KGOG 2018 Summer Workshop Uterine Cancer : 2018-07-29 0 902 2018-07-28
12 ¼­¿ï ´ëÇÑ¿µ»óÀÇÇÐȸ »ó±ÙÀÇ»ç À¯¹æÃÔ¿µ¿ëÀåÄ¡ Ç°Áú°ü¸® ±³À° 3ÀÏÂ÷(7¿ù29ÀÏ) : 2018-07-29 0 834 2018-07-28
11 ¼­¿ï ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2018³âµµ ¡ººÐ¼®½É¸®ÇÐ ±âÃÊ°­Á¡»: 2018-07-29 0 852 2018-07-28
10 ¼­¿ï °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 18 ȸ ü°èÀû ¹®Çå °íÂû[¸ÞŸºÐ¼®]À» ÅëÇÑ ³í¹®Ãâ°£ ¿öÅ©¼¥ : 2018-07-28 0 1,186 2018-07-28
9 °æ±â ¸íÁöº´¿ø ¿äÃò ¹× ½½°üÀý ÅëÁõ Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2018-07-28 0 1,150 2018-07-28
8 ¼­¿ï 2018³âµµ ´ëÇÑÅëÁõÇÐȸ Á¦3Â÷ CADAVER WORKSHOP : 2018-07-28 0 1,111 2018-07-28
7 ¼­¿ï ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ 2018³â ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ ¿¬¼ö°­Á : 2018-07-28 0 1,027 2018-07-28
6 °æ±â ´ëÇѳ»½Ã°æº¹°­°æ¿Ü°úÇÐȸ 2018 Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC) Symposium : 2018-07-28 0 1,271 2018-07-28
5 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø Hyperhidrosis Symposium : 2018-07-28 0 1,557 2018-07-28
4 ¼­¿ï °¡Å縯´ëÇб³¿©Àǵµ¼º¸ðº´¿ø 2018 The 11th Catholic Neurosurgery Update Symposium : 2018-07-28 0 1,434 2018-07-28
3 °æ±â ´ëÇÑ´ç´¢º´ÇÐȸ °æÀÎÁöȸEGDM (Essential Guideline to Diabetes Management) : 2018-07-28 0 2,241 2018-07-28
1411 | 1412 | 1413 | 1414 | 1415
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷